Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 4
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
Barbieri F, Bajetto A, Dellacasagrande I, Solari A, Würth R, Fernandez V, Rancati S, Ceresa D, Appolloni I, De Luca G, Dono M, Nozza P, Schiapparelli P, Gambaro M, Fiaschi P, Gaggero G, Costanzo N, Thellung S, Malatesta P, Pagano A, Zona G, De Pietri Tonelli D, Florio T. Barbieri F, et al. Among authors: de luca g. Neuro Oncol. 2023 Oct 3;25(10):1775-1787. doi: 10.1093/neuonc/noad076. Neuro Oncol. 2023. PMID: 37074930 Free PMC article.
Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G, Barabino E, Fedeli A, Ficarra G, Coco S, Russo A, Adamo V, Buemi F, Zullo L, Dono M, De Luca G, Longo L, Dal Bello MG, Tagliamento M, Alama A, Cittadini G, Pronzato P, Genova C. Rossi G, et al. Among authors: de luca g. Cancer Res. 2021 Feb 1;81(3):724-731. doi: 10.1158/0008-5472.CAN-20-0999. Epub 2020 Nov 4. Cancer Res. 2021. PMID: 33148663
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Morabito F, Gentile M, Monti P, Recchia AG, Menichini P, Skafi M, Atrash M, De Luca G, Bossio S, Al-Janazreh H, Galimberti S, Salah Z, Morabito L, Mujahed A, Hindiyeh M, Dono M, Fais F, Cutrona G, Neri A, Tripepi G, Fronza G, Ferrarini M. Morabito F, et al. Among authors: de luca g. Expert Opin Investig Drugs. 2020 Aug;29(8):869-880. doi: 10.1080/13543784.2020.1783239. Epub 2020 Jun 27. Expert Opin Investig Drugs. 2020. PMID: 32551999 Free article. Review.
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
De Luca G, Cerruti G, Lastraioli S, Conte R, Ibatici A, Di Felice N, Morabito F, Monti P, Fronza G, Matis S, Colombo M, Fabris S, Ciarrocchi A, Neri A, Menichini P, Ferrarini M, Nozza P, Fais F, Cutrona G, Dono M. De Luca G, et al. Hematol Oncol. 2022 Dec;40(5):962-975. doi: 10.1002/hon.3063. Epub 2022 Aug 18. Hematol Oncol. 2022. PMID: 35961859 Free PMC article.
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.
Marconi S, Croce M, Chiorino G, Rossi G, Guana F, Profumo A, Ostano P, Alama A, Longo L, De Luca G, Dono M, Dal Bello MG, Ponassi M, Rosano C, Romano P, Cavalieri Z, Grassi M, Tagliamento M, Zullo L, Venturi C, Dellepiane C, Mastracci L, Bennicelli E, Pronzato P, Genova C, Coco S. Marconi S, et al. Among authors: de luca g. Cancers (Basel). 2022 Jul 14;14(14):3412. doi: 10.3390/cancers14143412. Cancers (Basel). 2022. PMID: 35884472 Free PMC article.
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Monti P, Lionetti M, De Luca G, Menichini P, Recchia AG, Matis S, Colombo M, Fabris S, Speciale A, Barbieri M, Gentile M, Zupo S, Dono M, Ibatici A, Neri A, Ferrarini M, Fais F, Fronza G, Cutrona G, Morabito F. Monti P, et al. Among authors: de luca g. Sci Rep. 2020 Oct 28;10(1):18427. doi: 10.1038/s41598-020-75364-3. Sci Rep. 2020. PMID: 33116240 Free PMC article.
11 results